West Pharmaceutical Services Future Growth
Future criteria checks 1/6
West Pharmaceutical Services is forecast to grow earnings and revenue by 12.2% and 6.6% per annum respectively. EPS is expected to grow by 11.2% per annum. Return on equity is forecast to be 17.8% in 3 years.
Key information
12.2%
Earnings growth rate
11.2%
EPS growth rate
| Life Sciences earnings growth | 17.7% |
| Revenue growth rate | 6.6% |
| Future return on equity | 17.8% |
| Analyst coverage | Good |
| Last updated | 29 Jul 2024 |
Recent future growth updates
Recent updates
West Pharmaceutical Services, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
Jul 28
West Pharmaceutical: Continued Destocking And A High Valuation Post Q2 Results (Rating Maintained)
Jul 25Is It Time To Consider Buying West Pharmaceutical Services, Inc. (NYSE:WST)?
Jul 15We Think West Pharmaceutical Services (NYSE:WST) Can Stay On Top Of Its Debt
Jun 27Estimating The Fair Value Of West Pharmaceutical Services, Inc. (NYSE:WST)
May 21West Pharmaceutical: Pick And Shovels Of The Injectable Drug Industry
May 11West Pharmaceutical Services, Inc.'s (NYSE:WST) Business Is Yet to Catch Up With Its Share Price
Mar 30Is West Pharmaceutical Services (NYSE:WST) A Risky Investment?
Mar 12Why West Pharma Is Far From Done
Feb 28West Pharmaceutical Services, Inc.'s (NYSE:WST) Intrinsic Value Is Potentially 19% Below Its Share Price
Feb 20West Pharmaceutical Services: Still Too Expensive After The Recent Drop
Feb 20What Does West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Indicate?
Jan 10West Pharmaceutical: Great Business, Not So Great Valuation
Jan 08What West Pharmaceutical Services, Inc.'s (NYSE:WST) P/E Is Not Telling You
Dec 18West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Nov 27West Pharmaceutical Services: The Run Might Be Over
Oct 18Is West Pharmaceutical Services, Inc. (NYSE:WST) Potentially Undervalued?
Sep 24Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
Aug 22West Pharmaceutical: Revise To Buy On Exceptional Economic Characteristics
Aug 08What Is West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Doing?
Jun 26West Pharmaceutical: Hard To Justify The Price
May 26Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
May 16At US$330, Is It Time To Put West Pharmaceutical Services, Inc. (NYSE:WST) On Your Watch List?
Mar 20West Pharmaceutical Services' (NYSE:WST) Soft Earnings Don't Show The Whole Picture
Feb 28West Pharmaceutical Q4 2022 Earnings Preview
Feb 15West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Jan 31West Pharmaceutical: An Earnings Decline Seen In 2023, Shares Still Appear Expensive
Dec 19West Pharmaceutical declares $0.19 dividend
Dec 13Why West Pharmaceutical Services, Inc. (NYSE:WST) Could Be Worth Watching
Nov 29West Pharmaceutical Q3 2022 Earnings Preview
Oct 26West Pharmaceutical Services (NYSE:WST) Seems To Use Debt Rather Sparingly
Oct 25West Pharmaceutical Services: Shares Need To Get Cheaper To Make Sense
Oct 02Is West Pharmaceutical Services, Inc. (NYSE:WST) Expensive For A Reason? A Look At Its Intrinsic Value
Sep 14Is There Now An Opportunity In West Pharmaceutical Services, Inc. (NYSE:WST)?
Aug 31Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 3,360 | 703 | 614 | 910 | 7 |
| 12/31/2025 | 3,089 | 599 | 468 | 772 | 10 |
| 12/31/2024 | 2,873 | 484 | 213 | 587 | 9 |
| 6/30/2024 | 2,877 | 525 | 357 | 752 | N/A |
| 3/31/2024 | 2,929 | 569 | 386 | 757 | N/A |
| 12/31/2023 | 2,950 | 593 | 415 | 777 | N/A |
| 9/30/2023 | 2,927 | 559 | 420 | 768 | N/A |
| 6/30/2023 | 2,866 | 519 | 397 | 707 | N/A |
| 3/31/2023 | 2,884 | 552 | 410 | 711 | N/A |
| 12/31/2022 | 2,887 | 586 | 439 | 724 | N/A |
| 9/30/2022 | 2,909 | 631 | 388 | 654 | N/A |
| 6/30/2022 | 2,929 | 686 | 402 | 675 | N/A |
| 3/31/2022 | 2,881 | 684 | 382 | 647 | N/A |
| 12/31/2021 | 2,832 | 662 | 331 | 584 | N/A |
| 9/30/2021 | 2,681 | 613 | 341 | 572 | N/A |
| 6/30/2021 | 2,523 | 519 | 287 | 500 | N/A |
| 3/31/2021 | 2,326 | 423 | 307 | 504 | N/A |
| 12/31/2020 | 2,147 | 346 | 298 | 473 | N/A |
| 9/30/2020 | 2,037 | 312 | 272 | 430 | N/A |
| 6/30/2020 | 1,945 | 286 | 277 | 420 | N/A |
| 3/31/2020 | 1,888 | 261 | 247 | 377 | N/A |
| 12/31/2019 | 1,840 | 242 | 241 | 367 | N/A |
| 9/30/2019 | 1,792 | 230 | 215 | 334 | N/A |
| 6/30/2019 | 1,767 | 229 | 201 | 314 | N/A |
| 3/31/2019 | 1,745 | 219 | 186 | 291 | N/A |
| 12/31/2018 | 1,717 | 207 | 184 | 289 | N/A |
| 9/30/2018 | 1,711 | 155 | 193 | 297 | N/A |
| 6/30/2018 | 1,677 | 151 | 172 | 284 | N/A |
| 3/31/2018 | 1,627 | 133 | N/A | 288 | N/A |
| 12/31/2017 | 1,599 | 151 | N/A | 263 | N/A |
| 9/30/2017 | 1,566 | 190 | N/A | 254 | N/A |
| 6/30/2017 | 1,544 | 176 | N/A | 246 | N/A |
| 3/31/2017 | 1,535 | 182 | N/A | 237 | N/A |
| 12/31/2016 | 1,509 | 144 | N/A | 219 | N/A |
| 9/30/2016 | 1,487 | 138 | N/A | 216 | N/A |
| 6/30/2016 | 1,454 | 102 | N/A | 216 | N/A |
| 3/31/2016 | 1,426 | 85 | N/A | 217 | N/A |
| 12/31/2015 | 1,400 | 96 | N/A | 212 | N/A |
| 9/30/2015 | 1,390 | 94 | N/A | 190 | N/A |
| 6/30/2015 | 1,401 | 123 | N/A | 186 | N/A |
| 3/31/2015 | 1,411 | 133 | N/A | 172 | N/A |
| 12/31/2014 | 1,421 | 127 | N/A | 183 | N/A |
| 9/30/2014 | 1,414 | 119 | N/A | 206 | N/A |
| 6/30/2014 | 1,400 | 115 | N/A | 195 | N/A |
| 3/31/2014 | 1,376 | 108 | N/A | 210 | N/A |
| 12/31/2013 | 1,368 | 112 | N/A | 221 | N/A |
| 9/30/2013 | 1,347 | 110 | N/A | 222 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: WST's forecast earnings growth (12.2% per year) is above the savings rate (2.5%).
Earnings vs Market: WST's earnings (12.2% per year) are forecast to grow slower than the US market (15% per year).
High Growth Earnings: WST's earnings are forecast to grow, but not significantly.
Revenue vs Market: WST's revenue (6.6% per year) is forecast to grow slower than the US market (8.7% per year).
High Growth Revenue: WST's revenue (6.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: WST's Return on Equity is forecast to be low in 3 years time (17.8%).